Skip Navigation

European Journal of Heart Failure 2006 8(4):333-342; doi:10.1016/j.ejheart.2005.09.007
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Adamcová, M.
Right arrow Articles by Gersl, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adamcová, M.
Right arrow Articles by Gersl, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society of Cardiology

Myocardial regulatory proteins and heart failure

Michaela Adamcováa,*, Martin Sterbab, Tomás Simunekc, Anna Potácováa, Olga Popelováb and Vladimír Gerslb

a Department of Physiology, Faculty of Medicine in Hradec Králové, Charles University in Prague Simkova 870, 500 38 Hradec Králové, Czech Republic
b Department of Pharmacology, Faculty of Medicine in Hradec Králové, Charles University in Prague Simkova 870, 500 38 Hradec Králové, Czech Republic
c Department of Biochemical Sciences, Faculty of Pharmacy in Hradec Králové, Charles University in Prague Heyrovského 1203, 500 05 Hradec Králové, Czech Republic

* Corresponding author. Tel.: +420 49 5816180; fax: +420 49 5436054 E-mail address: adamcova{at}lfhk.cuni.cz


  Abstract

Cardiac troponin T (cTnT) and cardiac troponin I (cTnI) are considered to be the most specific and sensitive biochemical markers of myocardial damage. Troponins have been studied in a wide range of clinical settings, including heart failure; however, there are few data on the role of regulatory proteins in the pathogenesis of heart failure, although a few interesting hypotheses have been proposed. A considerable body of evidence favours the view that alteration of the myocardial thin filament is the primary event leading to defective contractility of the failing myocardium, while the changes in Ca2+ handling are a compensatory response. A better understanding of the role of regulatory proteins under different physiological and pathological conditions could lead to new therapeutic approaches in heart failure. Recently, calcium sensitisation has been proposed as a novel method by which cardiac performance may be enhanced via an increase in the affinity of troponin C for calcium but without affecting intracellular calcium concentration. To date, the only calcium sensitizer used in clinical practice is levosimendan.

Key Words: Heart failure • Regulatory proteins • Cardiac troponin • Cardiac marker • Calcium sensitizers • Myocardial stunning

Received November 9, 2004; Revised July 1, 2005; Accepted September 22, 2005


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ChestHome page
H. J. Bogaard, K. Abe, A. Vonk Noordegraaf, and N. F. Voelkel
The Right Ventricle Under Pressure: Cellular and Molecular Mechanisms of Right-Heart Failure in Pulmonary Hypertension
Chest, March 1, 2009; 135(3): 794 - 804.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.